Consun Pharmaceutical Group (HKG:1681) received approval from China's National Medical Products Administration to conduct a clinical trial of its chronic kidney disease drug candidate, SK-08, according to a Thursday filing with the Hong Kong bourse.
In addition, the regulator approved the Iodixanol injection developed by the drugmaker's unit, Guangzhou Consun Pharmaceutical, for cardiovascular angiography, cerebrovascular angiography, peripheral angiography, and other similar procedures, the filing said.
Price (HKD): $5.85, Change: $-0.02, Percent Change: -0.34%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments